>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:
  • WINT +16.9%, TIVO +13.6%, CSLT +12.7%, SNPS +7.6%, NTES +7.3%, KATE +6.8%, (also announce it is reviewing strategic alternatives) NTAP +5.3%
  • QUIK +4.2%, CRY +4.1%, SRCL +4%, NGD +3.9%, TPX +3.9%, ALXN +3.4%, LBTYA +3.3%, CIR +3.3%, GNCA +2.4%, NMIH +2.1%, GG +2%, ABX +2%
  • CHH +1.7%, CSCO +1.6%, SHPG +1.6%, EQIX +1.4%, AMAT +1.4%, SSNC +1.3%, PBFX +1.2%, GFI +1.2%, CVA +1%, TRP +1%
M&A news:
  • HGG +17.5% (HHGregg confirms plans to explore strategic alternatives)
  • RAD +2.6% (Walgreens (WBA) is optimistic regarding FTC approval for RAD M&A deal due to divesture package, according to NY Post)
  • BIDU +0.5% (acquired digital assistant startup Raven Tech, according to TechCrunch)
Other news:
  • XTLB +58.4% (continued strength), SCON +42.6% (receives a U.S. Patent enabled by STI's proprietary superconducting wire manufacturing method)
  • MDGS +37.4% (announces tha tthe China FDA has approved the commencement of the first multi-center MUSE Clinical Study in China)
  • CVRS +22.7% (Corindus Vascular Robotics announces a distribution agreement w/ a subsidiary of Mitsubishi (MSBHY); includes an initial order for 12 CorPath GRX Systems accompanied by an advance of $2 million toward the purchase price), RUBI +11% (still checking), BLDP +7.6% (receives 5-year, $25 mln deal Broad-Ocean Motor Co)
  • PGNX +5.6% (to join S&P SmallCap 600), SFLY +3.1% (to join S&P SmallCap 600)
  • VRX +2.6% (FDA approves Siliq to treat adults with moderate-to-severe plaque psoriasis)
  • TTM +2.3% (Tata Motors and and Microsoft (MSFT) India confirm that cos will collaborate on connected cars)
  • FOLD +2.1% (presents additional positive preliminary Phase 1/2 Data; demonstrates improving trends in majority of patients)
  • FL +1.3% (increases quarterly dividend to $0.31/share from $0.28/share; approves a new 3-year $1.2 bln share repurchase program extending through January 2020, replacing the previous $1 bln program; approves $277 mln capital expenditure program for 2017)
  • GSK +1% (in sympathy with SHPG earnings)
  • ALGN +0.9% (announces it has prevailed in proceedings initiated by ClearCorrect Operating that challenged the validity of three of its U.S. patents)
Analyst comments:
  • MDCA +4.6% (upgraded to Buy from Hold at Jefferies)